Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible
Valerio Gristina, Maria La Mantia, Marta Peri, Federica Iacono, Nadia Barraco, Alessandro Perez, Giuseppe Viscardi, Sofia Cutaia, Tancredi Didier Bazan Russo, Zubair Anwar, Lorena Incorvaia, Fabio Fulfaro, Salvatore Vieni, Gianni Pantuso, Giuseppa Graceffa, Antonio Russo, Antonio Galvano, Viviana Bazan
Abstract
Liquid biopsy has gained increasing interest in the growing era of precision medicine as minimally invasive technique. Recent findings demonstrated that detecting minimal or molecular residual disease (MRD) in NSCLC is a challenging matter of debate that need multidisciplinary competencies, avoiding the overtreatment risk along with achieving a significant survival improvement. This review aims to provide practical consideration for solving data interpretation questions about MRD in NSCLC thanks to the close cooperation between biologists and oncology clinicians. We discussed with a translational approach the critical point of view from benchside, bedside and bunchside to facilitate the future applicability of liquid biopsy in this setting. Herein, we defined the clinical significance of MRD, focusing on relevant practical consideration about advantages and disadvantages, speculating on future clinical trial design and standardization of MRD technology.